| GTO ID | GTC1902 |
| Trial ID |
NCT03548207
|
| Disease |
Multiple Myeloma
|
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Carvykti|Ciltacabtagene Autoleucel|Cilta-cel|JNJ-68284528 |
| Location approved | US, EU, UK, Japan, Australia, Canada |
| Generation | 2nd |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma |
| Year | 2018 |
| Country | Japan |
| Company sponsor | Janssen Research & Development, LLC |
| Other ID(s) | CR108480|2018-000121-32|68284528MMY2001 |